The research introduces what its authors call a cardiotocography age, an AI-derived measure modeled loosely on the idea of biological age. Rather than asking whether a fetal heart tracing looks reassuring or non-reassuring in the moment, the algorithm was trained to estimate where a given pregnancy sits along a developmental trajectory inferred from thousands of prior recordings. The gap between the cardiotocography age the model assigns and the actual gestational age of the fetus serves as the digital biomarker. When that gap widens in one direction, the researchers report, it flags pregnancies at elevated risk of adverse outcomes such as hypertensive complications, fetal growth restriction, and emergency operative delivery.

The underlying insight is that a fetal heart rate pattern is not merely a snapshot of moment-to-moment oxygenation but a composite signature of autonomic nervous system maturation, placental function, and intrauterine environment. Cardiologists learned something analogous when they discovered that a machine can read an electrocardiogram and estimate a patient’s physiological age; hearts that look older than their chronological age tend to belong to people at higher cardiovascular risk. The npj Women’s Health study transfers that logic to the fetus, arguing that the heart rate variability, baseline trends, accelerations, and decelerations inscribed on a cardiotocography strip encode a quantifiable signature of developmental maturity.

Technically, the approach rests on deep learning applied to raw cardiotocographic signals rather than to the summary indices clinicians typically compute. Conventional analysis reduces a tracing to a handful of features, such as baseline heart rate, variability bands, and the count of accelerations and decelerations, each defined by consensus criteria drafted before modern computing. These parameters are individually weak predictors, and large trials of computerized cardiotocography interpretation have historically failed to show that automated alerts improve outcomes, partly because the features were chosen by human intuition decades ago. The new model instead learns its own representations directly from the continuous signal, using architectures capable of detecting temporal patterns too subtle or too diffuse for the standard feature set to capture.

Training such a model requires careful handling of a notorious problem in fetal monitoring: the labels are noisy and the populations are imbalanced. Adverse outcomes are, fortunately, rare relative to the number of recordings collected, which means an algorithm can achieve deceptively high accuracy by simply predicting that everything is fine. The researchers addressed this through appropriate validation design, holding out complete cohorts for testing and evaluating the model against outcomes that had not yet occurred at the time of the recording. This temporal separation matters enormously. Many earlier machine learning studies in obstetrics tested their algorithms on tracings taken during labor and then predicted outcomes of that same labor, a design that risks simply detecting the crisis already underway. The cardiotocography age concept is explicitly forward-looking, derived from antenatal recordings and validated against complications arising later in the pregnancy.

The reported performance suggests the biomarker has genuine discriminative power. Pregnancies whose AI-assigned cardiotocography age lagged behind their gestational age clustered disproportionately among those that later developed hypertensive disorders of pregnancy, delivered growth-restricted infants, or required urgent cesarean sections for fetal compromise. The signal held up after adjustment for conventional risk factors, meaning the model was not merely rediscovering maternal age, body mass index, or pre-existing hypertension, information clinicians already collect. Instead, the fetal heart tracing itself appeared to contain additive information, a conclusion that, if replicated across diverse populations, would justify incorporating the measure into routine antenatal assessment alongside ultrasound and blood pressure monitoring.

Why should a heart rate pattern recorded weeks before symptoms predict a disorder like preeclampsia, which is conventionally understood as a placental disease manifesting through maternal hypertension? The most plausible explanation lies in the shared biology of placental insufficiency. When the placenta fails to establish adequate perfusion, the fetus adapts, redistributing blood flow and modulating autonomic tone in ways that subtly reshape heart rate dynamics long before growth falters or maternal blood pressure rises. These adaptations leave traces in the variability and periodicity of the fetal electrocardiographic signal captured at the maternal abdomen. In effect, the algorithm learns to recognize the physiological fingerprint of a struggling placenta, converting it into a number that clinicians can act on.

The digital biomarker framing carries implications beyond any single disease. Precision-medicine researchers have increasingly argued that pregnancy is an ideal proving ground for continuous, physiological, computationally interpretable data, because the obstetric population is monitored intensively and the outcomes are discrete and consequential. A validated cardiotocography age could function as a longitudinal vital sign for the fetus, tracked across visits like blood pressure or fetal growth percentiles. Deviation from the expected trajectory would trigger targeted surveillance: serial growth scans, Doppler studies of umbilical artery flow, or low-dose aspirin prophylaxis in cases where risk models currently rely on coarse demographic and biophysical screening. The measure could also serve as an endpoint in clinical trials of interventions designed to improve placental function, replacing months of waiting with a computable surrogate readout.

Significant hurdles remain before the metric enters practice. The study’s training data reflect the equipment, acquisition protocols, and population characteristics of the institutions that contributed recordings, and cardiotocographic signals are sensitive to gestational age in ways that demand robust calibration across the full range of pregnancy. Regulatory pathways for adaptive algorithms in medical devices are still maturing, and clinicians will reasonably ask what they should do with a risk score in the absence of trials demonstrating that acting on it improves outcomes. History counsels humility: electronic fetal monitoring itself was adopted worldwide on physiological plausibility alone, and only later did randomized trials reveal that its widespread use had reduced neonatal seizures while dramatically increasing cesarean rates without lowering cerebral palsy incidence. A new biomarker built on the same signal must clear a higher evidentiary bar than its predecessor did.

Yet the conceptual achievement is difficult to overstate. The study demonstrates that an ordinary, ubiquitous clinical recording, taken with equipment already installed in virtually every maternity unit on earth, contains information about future pregnancy health that decades of expert interpretation never systematically extracted. If subsequent multi-center validation confirms the findings across populations and devices, the cardiotocography age could join the growing family of AI-derived organ ages, alongside brain age, heart age, and retinal age, that are reshaping how medicine quantifies risk. For a field in which the central tools have remained essentially unchanged since the 1960s, the prospect of turning the labor ward’s oldest instrument into a predictive window on the pregnancy’s future marks a genuinely new chapter in fetal medicine.

Subject of Research: An AI-derived cardiotocography age biomarker that predicts future adverse pregnancy outcomes from routine fetal heart rate recordings

Article Title: AI-derived cardiotocography age as a digital biomarker for predicting future adverse pregnancy outcomes

Article References: Gu, J., Lin, Z., Ma, J., Wang, J., Zhang, L., Bai, R., Tu, Z., Jiang, Y., Xie, D., Zhou, Y., Liu, G., & Hong, S. (2026). AI-derived cardiotocography age as a digital biomarker for predicting future adverse pregnancy outcomes. npj Women's Health. https://doi.org/10.1038/s44294-026-00165-4

Image Credits: AI Generated

DOI: 10.1038/s44294-026-00165-4

Keywords: artificial intelligence, cardiotocography, digital biomarker, pregnancy outcomes, fetal heart rate monitoring, preeclampsia, fetal growth restriction, deep learning, maternal-fetal medicine, predictive analytics, placental insufficiency, npj Women's Health